Path analysis diagram illustrating the associations between alexithymia, social support, anticipated stigma and patient satisfaction, with their respective correlation coefficients... by Keya Bibikar (22386306)

P values of Kruskal–Wallis test at 95% significance level. by Fahd Saeed Alakbari (10701871)

Subjects:

Table 1_Increased frequencies of human Th-17 CD4+ T-cells and decreased T-regulatory cells in patients with early and advanced metabolic dysfunction-associated steatotic liver dise... by Elżbieta Supruniuk (16736637)

Table 2_Increased frequencies of human Th-17 CD4+ T-cells and decreased T-regulatory cells in patients with early and advanced metabolic dysfunction-associated steatotic liver dise... by Elżbieta Supruniuk (16736637)

Generation of prime numbers based on a range. by Amal Ezz-Eldien (20235128)

“…More notably, our algorithms exhibit the unique ability to provide prime numbers from range to range with a commendable performance. This substantial enhancement in performance and adaptability can significantly impact the effectiveness of various applications that depend on prime numbers, from cryptographic systems to distributed computing. …”

Comparative Analysis of Chills Experience Across Three Groups: This table presents a detailed comparison of three groups (A, B, and C) in terms of their experiences with chills. It... by Felix Alexandre Schoeller (20988295)

Subjects:

<i>N. parisii</i> infection is not significantly changed in <i>C. elegans</i> sphingolipid biosynthesis mutants. by Hala Tamim El Jarkass (16625309)

Subjects:

Two-way ANCOVA results for Task 1. The bold values highlight statistically significant results of Task 1. by Mucahit Gemici (21519313)

One-way ANCOVA results for Task 2. The bold values highlight statistically significant results of Task 2. by Mucahit Gemici (21519313)

Summary of post-treatment disease course measures from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Study selection criteria. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

Subjects:

Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

Subjects:

PICOS criteria for the SLR. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. by Filip Stanicic (17808254)

Subjects:

Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment disease course measures from clinical trials with psychotherapies. by Filip Stanicic (17808254)

Subjects:

PRISMA flow chart. by Filip Stanicic (17808254)

Subjects: